Last reviewed · How we verify
Dexmedetomidine bolus and high infusion-Propofol — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Dexmedetomidine bolus and high infusion-Propofol (Dexmedetomidine bolus and high infusion-Propofol) — Joseph Cravero.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Dexmedetomidine bolus and high infusion-Propofol TARGET | Dexmedetomidine bolus and high infusion-Propofol | Joseph Cravero | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Dexmedetomidine bolus and high infusion-Propofol CI watch — RSS
- Dexmedetomidine bolus and high infusion-Propofol CI watch — Atom
- Dexmedetomidine bolus and high infusion-Propofol CI watch — JSON
- Dexmedetomidine bolus and high infusion-Propofol alone — RSS
Cite this brief
Drug Landscape (2026). Dexmedetomidine bolus and high infusion-Propofol — Competitive Intelligence Brief. https://druglandscape.com/ci/dexmedetomidine-bolus-and-high-infusion-propofol. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab